Wayde McMillan Elected to Hologic Board of Directors
Hologic (NASDAQ: HOLX) has announced the election of Wayde McMillan to its Board of Directors, effective April 4, 2025. McMillan will also serve on the company's Audit and Finance Committee.
McMillan brings significant healthcare financial expertise, currently serving as CFO of Solventum since 2024, following his role as CFO of 3M Company's Health Care Business Group. His previous positions include Executive VP, CFO and Treasurer at Insulet (2019-2023), and CFO of Medtronic's Minimally Invasive Therapies Group (2015-2019). He also held various leadership roles at Covidien from 2006 to 2015.
McMillan holds a BS in Business Administration from Merrimack College and an MBA from Bentley University's McCallum Graduate School of Business.
Hologic (NASDAQ: HOLX) ha annunciato l'elezione di Wayde McMillan nel suo Consiglio di Amministrazione, con effetto dal 4 aprile 2025. McMillan servirà anche nel Comitato di Audit e Finanza dell'azienda.
McMillan porta con sé una significativa esperienza finanziaria nel settore sanitario, attualmente ricoprendo il ruolo di CFO di Solventum dal 2024, dopo aver ricoperto il ruolo di CFO del Gruppo Salute della 3M Company. Le sue esperienze precedenti includono Executive VP, CFO e Tesoriere presso Insulet (2019-2023) e CFO del Gruppo Terapie Minimamente Invasive di Medtronic (2015-2019). Ha anche ricoperto vari ruoli di leadership in Covidien dal 2006 al 2015.
McMillan ha conseguito una laurea in Amministrazione Aziendale presso il Merrimack College e un MBA presso la McCallum Graduate School of Business della Bentley University.
Hologic (NASDAQ: HOLX) ha anunciado la elección de Wayde McMillan para su Junta Directiva, con efecto a partir del 4 de abril de 2025. McMillan también formará parte del Comité de Auditoría y Finanzas de la empresa.
McMillan aporta una experiencia financiera significativa en el sector de la salud, actualmente ocupando el cargo de CFO de Solventum desde 2024, tras su rol como CFO del Grupo de Salud de 3M Company. Sus posiciones anteriores incluyen VP Ejecutivo, CFO y Tesorero en Insulet (2019-2023) y CFO del Grupo de Terapias Mínimamente Invasivas de Medtronic (2015-2019). También ocupó varios roles de liderazgo en Covidien desde 2006 hasta 2015.
McMillan tiene una licenciatura en Administración de Empresas del Merrimack College y un MBA de la McCallum Graduate School of Business de la Bentley University.
Hologic (NASDAQ: HOLX)는 Wayde McMillan을 이사회의 새로운 멤버로 선출했다고 발표했습니다. 이 임명은 2025년 4월 4일부터 효력을 발휘합니다. McMillan은 회사의 감사 및 재무 위원회에서도 활동할 예정입니다.
McMillan은 2024년부터 Solventum의 CFO로 재직하며 의료 재무 분야에서 상당한 전문성을 보유하고 있습니다. 그는 이전에 3M Company의 헬스케어 사업부 CFO로 일했습니다. 그의 이전 직책에는 Insulet에서의 임원 부사장, CFO 및 재무부장(2019-2023)과 Medtronic의 최소 침습 치료 그룹 CFO(2015-2019)가 포함됩니다. 그는 2006년부터 2015년까지 Covidien에서 여러 리더십 역할을 맡았습니다.
McMillan은 Merrimack College에서 경영학 학사 학위를, Bentley University의 McCallum Graduate School of Business에서 MBA를 취득했습니다.
Hologic (NASDAQ: HOLX) a annoncé l'élection de Wayde McMillan à son Conseil d'Administration, prenant effet le 4 avril 2025. McMillan siégera également au Comité d'Audit et de Finances de l'entreprise.
McMillan apporte une expertise financière significative dans le domaine de la santé, occupant actuellement le poste de CFO de Solventum depuis 2024, après avoir été CFO du Groupe Santé de 3M Company. Ses précédents postes incluent Vice-Président Exécutif, CFO et Trésorier chez Insulet (2019-2023) et CFO du Groupe de Thérapies Minimally Invasives de Medtronic (2015-2019). Il a également occupé divers postes de direction chez Covidien de 2006 à 2015.
McMillan est titulaire d'un BS en Administration des Affaires du Merrimack College et d'un MBA de la McCallum Graduate School of Business de l'Université Bentley.
Hologic (NASDAQ: HOLX) hat die Wahl von Wayde McMillan in seinen Vorstand bekannt gegeben, die am 4. April 2025 wirksam wird. McMillan wird auch im Audit- und Finanzausschuss des Unternehmens tätig sein.
McMillan bringt umfassende finanzielle Fachkenntnisse im Gesundheitswesen mit und ist seit 2024 CFO von Solventum, nachdem er als CFO der Gesundheitsabteilung der 3M Company tätig war. Zu seinen vorherigen Positionen gehören Executive VP, CFO und Schatzmeister bei Insulet (2019-2023) sowie CFO der Gruppe für minimalinvasive Therapien bei Medtronic (2015-2019). Zudem hatte er von 2006 bis 2015 verschiedene Führungspositionen bei Covidien inne.
McMillan hat einen Bachelor-Abschluss in Betriebswirtschaft von der Merrimack College und einen MBA von der McCallum Graduate School of Business der Bentley University.
- Addition of experienced healthcare industry CFO to the board strengthens financial oversight
- Brings extensive med-tech industry expertise from leadership roles at major companies (3M, Insulet, Medtronic, Covidien)
- Strategic appointment to Audit and Finance Committee leverages his financial background
- None.
Mr. McMillan has served as the Chief Financial Officer of Solventum Corporation, a carve-out health care company of 3M Company, since 2024 after serving as the Chief Financial Officer of 3M Company’s Health Care Business Group since November 2023. Previously, Mr. McMillan served as Executive Vice President, Chief Financial Officer and Treasurer of Insulet Corporation, a medical device company, from March 2019 to November 2023. From January 2015 to February 2019, he was Chief Financial Officer and Vice President of Finance of the Minimally Invasive Therapies Group at Medtronic plc, a medical device company. From November 2006 to January 2015, prior to Medtronic’s acquisition of Covidien plc, a medical device company, Mr. McMillan held a variety of leadership positions at Covidien. Mr. McMillan started his career in accounting, audit, financial analysis and investor relations positions at various institutions.
“We’re thrilled to welcome Wayde to Hologic’s Board of Directors,” said Steve MacMillan, Hologic’s Chairman, President and Chief Executive Officer. “His extensive financial expertise and deep understanding of the med-tech industry will be great complements to our current Board.”
Mr. McMillan earned his Bachelor of Science degree in Business Administration from Merrimack College and an MBA from Bentley University’s McCallum Graduate School of Business.
About Hologic, Inc.
Hologic, Inc. is an innovative medical technology company primarily focused on improving women's health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com.
Forward Looking Statements
This press release contains forward-looking information that involves risks and uncertainties, including statements about the Company's plans, objectives, expectations and intentions, and statements regarding the Company's Board of Directors. These forward-looking statements are based on assumptions made by the Company as of this date and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those anticipated. These risks include, but are not limited to, the risk that the Company may not be able to attract and retain qualified Board members or executives. These risks are not exhaustive. Other factors that could adversely affect the Company's business and prospects are described in the filings made by the Company with the SEC. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented here to reflect any change in expectations or any change in events, conditions or circumstances on which any such statements are based.
SOURCE: Hologic, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250404530519/en/
Michael Watts
Corporate Vice President, Investor Relations
Michael.Watts@hologic.com
(858) 410-8514
Bridget Perry
Senior Director, Corporate Communications
Bridget.Perry@hologic.com
(508) 263-8654
Source: Hologic, Inc.
FAQ
When will Wayde McMillan join Hologic's Board of Directors?
What committees will Wayde McMillan serve on at Hologic (HOLX)?
What is Wayde McMillan's current position before joining HOLX's board?
What is Wayde McMillan's healthcare industry experience before joining Hologic's board?
